Provided by Tiger Trade Technology Pte. Ltd.

Design Therapeutics, Inc.

14.80
-0.2200-1.46%
Post-market: 14.800.00000.00%19:30 EDT
Volume:653.00K
Turnover:9.64M
Market Cap:924.13M
PE:-12.52
High:15.00
Open:14.81
Low:14.51
Close:15.02
52wk High:17.25
52wk Low:5.28
Shares:62.44M
Float Shares:37.01M
Volume Ratio:1.01
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1816
EPS(LYR):-1.2174
ROE:-34.13%
ROA:-22.53%
PB:4.58
PE(LYR):-12.16

Loading ...

Design Therapeutics Stockholders Approve Director and Auditor at Meeting

TIPRANKS
·
Jun 12

Design Therapeutics shareholders elect Simeon George to board at annual meeting

Reuters
·
Jun 12

Design Therapeutics management to join Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)

TIPRANKS
·
May 27

Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX)

TIPRANKS
·
May 20

Analysts’ Top Healthcare Picks: Neuren Pharmaceuticals Limited (NURPF), Design Therapeutics (DSGN)

TIPRANKS
·
May 19

Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk

Dow Jones
·
May 19

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, BlackRock TCP Capital, Boston Scientific

Reuters
·
May 19

BUZZ-Design Therapeutics falls after early-stage data for genetic disorder treatment

Reuters
·
May 18

Larimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics

TIPRANKS
·
May 18

Design Therapeutics Inc : RBC Raises Target Price to $20 From $14

THOMSON REUTERS
·
May 18

Design Therapeutics reports positive Phase 1/2 DT-216P2 data

TIPRANKS
·
May 18

Design Therapeutics' DT-216P2 Shows Clinical Improvements in Friedreich Ataxia Trial; Shares Rise Pre-Bell

MT Newswires Live
·
May 18

Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial

TIPRANKS
·
May 18

Design Therapeutics Inc - DT-216P2 Improves Patient-Reported Fatigue by Over Five Points After Four Weeks

THOMSON REUTERS
·
May 18

Design Therapeutics Announces Four-Week Iv Data From the Restore-Fa Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

THOMSON REUTERS
·
May 18

Design Therapeutics Inc - DT-216P2 at 1 Mpk Improves M-Fars by 6.4 Points and Upright Stability by 2.7 Points

THOMSON REUTERS
·
May 18

Design Therapeutics Inc - to Pursue Registrational Development for DT-216P2, Update in Q4 2026

THOMSON REUTERS
·
May 18

Design Therapeutics Inc - DT-216P2 Generally Well-Tolerated With No Serious Adverse Events Reported

THOMSON REUTERS
·
May 18

Design Therapeutics to present Phase 1/2 DT-216P2 Friedreich’s ataxia trial data May 18

Reuters
·
May 18